Real-world Data (RWD) of Ramucirumab Plus Paclitaxel

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

222 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-30

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Real World Data (RWD) obtained from real clinical sites is data obtained after administering a drug to patients with different characteristics in daily practice, and Real World Evidence (RWE) is established based on RWD. It is possible to overcome the disadvantage of RCT, which cannot reflect all the various variables in the actual clinical field as it is conducted for only subset of patients.

Researchers planned to prospectively collect RWD of ramucirumab/paclitaxel combination therapy as 2nd-line chemotherapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Retrospective Study of Ramucirumab and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

NCT04192734

Gastric or Gastroesophageal Junction Adenocarcinoma

COMPLETED

Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis

NCT02628951

Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

COMPLETED PHASE2

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

NCT02898077

Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma

COMPLETED PHASE3

Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy

NCT01497964

Gastric Cancer

COMPLETED PHASE1/PHASE2

Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer

NCT02072317

Advanced Gastric Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Most drugs are introduced into the medical market based on efficacy derived from randomized controlled trials (RCTs) in a subset of patient groups in which the age, presence of comorbidities, and general conditions of the target patient are strictly controlled by the researcher.

Real World Data (RWD) obtained from real clinical sites is data obtained after administering a drug to patients with different characteristics in daily practice, and Real World Evidence (RWE) is established based on RWD. It is possible to overcome the disadvantage of RCT, which cannot reflect all the various variables in the actual clinical field as it is conducted for only subset of patients.

Researchers have collected retrospective RWD from patients who used ramucirumab/paclitaxel in a previous study (KCSG ST19-16). Considering the limitations of RWD obtained through retrospective data collection, it is necessary to generate RWE through RWD, which prospectively collects various clinical data obtained in the process of using new anticancer drugs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer Gastroesophageal Junction Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prospective population

The target group for the purpose of prospectively collecting the clinical data (RWD) of patients using ramucirumab/paclitaxel as 2nd-line chemotherapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Ramucirumab and paclitaxel

Intervention Type DRUG

Ramucirumab/paclitaxel as a second-line chemotherapy after May 1, 2018, when health insurance coverage for the combination therapy started

Historical retrospective population

The target group for the purpose of retrospectively collecting the clinical data (RWD) of patients who have failed platinum-based palliative first-line therapy, and who started the following second-line therapy: taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy, before May 1, 2018, when health insurance coverage for the ramucirumab/paclitaxel combination therapy started in South Korea.

Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy

Intervention Type DRUG

Taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy as a second-line therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ramucirumab and paclitaxel

Ramucirumab/paclitaxel as a second-line chemotherapy after May 1, 2018, when health insurance coverage for the combination therapy started

Intervention Type DRUG

Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy

Taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy as a second-line therapy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prospective population Historical retrospective population

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 19 years or older and histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma
* Patients with locally advanced or metastatic disease for which curative resection is not possible.
* Patients who have failed fluoropyrimidine and platinum (cisplatin or oxaliplatin)-based chemotherapy as palliative first-line therapy
* Patients who is starting ramucirumab/paclitaxel combination therapy after the study initiation date

* Patients aged 19 years or older and histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma
* Patients with locally advanced or metastatic disease for which curative resection is not possible
* Patients who have failed platinum-based palliative first-line therapy, and who started the following second-line therapy: taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy, before May 1, 2018

Exclusion Criteria

* Patients receiving ramucirumab monotherapy
* Patients receiving ramucirumab/paclitaxel in clinical trial or receiving without being covered by health insurance
* Patients unable to communicate or incapable of understanding documents for patient report outcomes
2. Historical retrospective population

* Patients receiving ramucirumab monotherapy
* Patients receiving ramucirumab/paclitaxel in clinical trial or receiving without being covered by health insurance

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No